RxDoctor Payments Data

Hormazd Sanjana, MD

Family Medicine · San Antonio, TXNPI 1093706293

Payments from drug & device makers

$16,968in general payments, 2019–2025

Across 968 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$2K
  • Novo Nordisk$2K
  • GSK$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$622
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$16,935100%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca142$2,623
AbbVie(2 entities)139$2,250
Novo Nordisk112$2,054
GSK106$1,488
Lilly USA, LLC93$1,296
Boehringer Ingelheim31$622
Merck31$527
Abiomed6$467
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)26$450
Pfizer22$359
Johnson & Johnson21$323
Sanofi-aventis U.S. LLC17$301
Abbott12$257
Kaleo, Inc.10$250
Amarin Pharma, Inc.16$226
Amgen(2 entities)13$221
Takeda Pharmaceuticals U.S.A., Inc.10$187
Axsome Therapeutics, Inc.8$171
Inspire Medical Systems, Inc.2$167
Sunovion Pharmaceuticals Inc.10$166
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$156
Shield Therapeutics Inc9$148
Viiv Healthcare Company7$146
Novartis4$125
ARS Pharmaceuticals Operations, Inc.1$124
Bayer5$121
Gilead7$113
Astellas Pharma US Inc7$113
Esperion Therapeutics, Inc.7$111
Supernus Pharmaceuticals, Inc.6$105
Idorsia Pharmaceuticals US Inc6$96
Dynavax Technologies Corporation5$70
Sumitomo Pharma America, Inc.4$64
Organon3$64
Biohaven Pharmaceutical Holding Company Ltd.3$61
Ironshore Pharmaceuticals Inc.3$58
Genentech USA, Inc.3$52
Teva Pharmaceuticals USA, Inc.3$49
Eisai Inc.3$47
Tris Pharma Inc2$44
Bardy Diagnostics, Inc.3$44
Dexcom, Inc.2$44
Sanofi Pasteur Inc.2$42
Alk-abello, Inc2$40
Otsuka America Pharmaceutical, Inc.2$39
Corcept Therapeutics2$36
Althera Pharmaceuticals LLC3$35
Si-bone, Inc.2$34
Mannkind Corporation2$34
Medtronic2$33
Optinose US, Inc.2$31
Cvrx, Inc.1$29
Bausch Health US, LLC2$26
Shire North American Group Inc2$26
BD1$23
Cipher Pharmaceuticals US LLC1$21
Exact Sciences1$21
Corium, LLC1$16
Adlon Therapeutics L.p.1$16
Optos, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,968 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$697,429
Medicare patients
580
Services billed
55,970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide138$195,110
FarxigaDapagliflozin Propanediol66$80,968
MounjaroTirzepatide59$76,035
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$74,825
JardianceEmpagliflozin64$71,266
Xigduo XrDapaglifloz Propaned/Metformin86$71,265
JanuviaSitagliptin Phosphate47$62,443
RybelsusSemaglutide30$48,505
TrulicityDulaglutide40$43,752
MyrbetriqMirabegron31$37,927
VraylarCariprazine Hcl15$27,254
Janumet XrSitagliptin Phos/Metformin Hcl26$20,335
Tresiba Flextouch U-200Insulin Degludec22$19,493
EliquisApixaban21$16,489
Breo ElliptaFluticasone/Vilanterol17$11,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,054$243,615168 claims
Lilly USA, LLCMounjaro, Trulicity$1,296$119,78799 claims
GSKTrelegy Ellipta, Breo Ellipta$1,488$86,27095 claims
AstraZenecaFarxiga, Symbicort$2,623$84,91881 claims
MerckJanuvia, Janumet Xr$527$82,77873 claims
Boehringer IngelheimJardiance$622$71,26664 claims
Astellas Pharma US IncMyrbetriq$113$37,92731 claims
AbbVieVraylar$2,250$27,25415 claims
PfizerEliquis$359$16,48921 claims
Johnson & JohnsonXarelto$323$8,47513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →